PellePharm's Series B - III Round

PellePharm raised a round of funding on July 31, 2017. Investors include BridgeBio Pharma.

PellePharm is developing topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients.…

Articles about PellePharm's Series B - III Round: